Its proposed role in enhancing cellular DNA repair and supporting the skin’s response to ultraviolet-induced damage has prompted investigation into whether supplementation may reduce skin cancer incidence in individuals at elevated risk. Current evidence suggests that nicotinamide may represent a safe, accessible, and relatively inexpensive strategy for skin cancer prevention in predisposed populations.
Clinical results with nattokinase have been inconsistent—and dose may be the reason. A 1,062-patient study using 10,800 FU/day reported significant changes in lipids and carotid plaque, reopening a key question for practitioners.
Today’s cardiometabolic care is moving beyond a singular focus on LDL cholesterol toward a more comprehensive therapeutic strategy. Properly formulated and prescribed, niacin merits renewed consideration as an evidence-based nutritional intervention that favorably impacts multiple lipid parameters associated with atherosclerotic CVD.
A systematic review found that extended-release wax-matrix niacin improved several blood lipid measures, while also highlighting the need to monitor fasting blood glucose.
A six-week randomized, double-blind, placebo-controlled trial compared 1,500 mg/day of wax-matrix extended-release niacin with the same dose of inositol hexanicotinate, often marketed as “no-flush” niacin. Wax-matrix niacin significantly reduced total cholesterol, LDL cholesterol, and non-HDL cholesterol while increasing HDL cholesterol. Inositol hexanicotinate produced no significant lipid improvements compared with placebo. A small pharmacokinetic substudy also found evidence of niacin absorption with the wax-matrix formulation but no meaningful bioavailability with inositol hexanicotinate.
Nicotinic acid has a distinctive role in nutritional lipid support. By influencing free-fatty-acid release, hepatic triglyceride production, and VLDL synthesis, niacin works upstream in lipid metabolism. Published clinical research has also examined its effects on lipoprotein(a), an important largely inherited cardiovascular biomarker. This article explores niacin’s mechanisms, its relationship with NAD+, and how extended-release delivery may help address flushing and improve long-term adherence.
For decades, clinicians have focused on which nutrients to recommend and at what dose. But a growing body of research suggests another variable may be just as important: how those nutrients are delivered to the body over time. Most supplements on the market—whether powders, capsules, liquids, or standard tablets—release theirRead
Patients often stop taking supplements not because they reject the protocol, but because the regimen creates too much friction. Learn how practitioners can improve adherence through simpler dosing, predictable delivery, patient education, and early follow-up.
